Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATTNYSE:SNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/ASNNSmith & Nephew$30.30+3.5%$27.58$23.69▼$31.72$13.27B0.68788,907 shs897,246 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%SNNSmith & Nephew+3.53%+5.10%+6.36%+1.47%+15.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASNNSmith & Nephew2.1077 of 5 stars1.03.02.50.02.60.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/ASNNSmith & Nephew 2.00Hold$28.00-7.60% DownsideCurrent Analyst Ratings BreakdownLatest JAI, ATT, SNN, and BHMU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025SNNSmith & NephewCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$27.00 ➝ $28.004/25/2025SNNSmith & NephewHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/25/2025SNNSmith & NephewHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/17/2025SNNSmith & NephewCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$27.00 ➝ $27.003/12/2025SNNSmith & NephewUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/ASNNSmith & Nephew$5.81B2.28$3.79 per share8.00$11.94 per share2.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ASNNSmith & Nephew$263M$2.1614.0315.151.26N/AN/AN/A8/5/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/ASNNSmith & Nephew$0.892.94%N/A41.20%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/ASNNSmith & Nephew0.632.511.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/ASNNSmith & Nephew25.64%Insider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/ASNNSmith & Nephew1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableSNNSmith & Nephew20,100437.96 million432.83 millionOptionableJAI, ATT, SNN, and BHMU HeadlinesRecent News About These CompaniesSmith & Nephew plc (NYSE:SNN) Shares Purchased by NBC Securities Inc.June 6 at 4:26 AM | marketbeat.comSmith & Nephew plc (NYSE:SNN) Short Interest Up 22.9% in MayJune 4 at 11:06 PM | marketbeat.comBank of America Corp DE Sells 266,704 Shares of Smith & Nephew plc (NYSE:SNN)June 1, 2025 | marketbeat.comSmith & Nephew SNATS, Inc. Common Stock (SNN)May 31, 2025 | nasdaq.comVident Advisory LLC Grows Stock Holdings in Smith & Nephew plc (NYSE:SNN)May 28, 2025 | marketbeat.comSmith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of DefenseMay 27, 2025 | globenewswire.comBNP Paribas Financial Markets Buys Shares of 17,709 Smith & Nephew plc (NYSE:SNN)May 27, 2025 | marketbeat.comBarrow Hanley Mewhinney & Strauss LLC Reduces Holdings in Smith & Nephew plc (NYSE:SNN)May 25, 2025 | marketbeat.comQuantinno Capital Management LP Has $2.40 Million Holdings in Smith & Nephew plc (NYSE:SNN)May 23, 2025 | marketbeat.com249,488 Shares in Smith & Nephew plc (NYSE:SNN) Purchased by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Receives Average Rating of "Hold" from BrokeragesMay 22, 2025 | marketbeat.comWexford Capital LP Buys Shares of 22,000 Smith & Nephew plc (NYSE:SNN)May 21, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Shares Sold by Tpg Gp A LLCMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Holdings in Smith & Nephew plc (NYSE:SNN)May 20, 2025 | marketbeat.comNorthern Trust Corp Grows Stock Position in Smith & Nephew plc (NYSE:SNN)May 19, 2025 | marketbeat.comEthic Inc. Reduces Position in Smith & Nephew plc (NYSE:SNN)May 17, 2025 | marketbeat.comJane Street Group LLC Takes $2.83 Million Position in Smith & Nephew plc (NYSE:SNN)May 17, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires Shares of 43,255 Smith & Nephew plc (NYSE:SNN)May 16, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 96,285 Shares of Smith & Nephew plc (NYSE:SNN)May 15, 2025 | marketbeat.comJ. Goldman & Co LP Purchases Shares of 1,940,582 Smith & Nephew plc (NYSE:SNN)May 13, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Stock Position Trimmed by Mercer Global Advisors Inc. ADVMay 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookBy Chris Markoch | May 29, 2025View Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookJAI, ATT, SNN, and BHMU Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Smith & Nephew NYSE:SNN$30.30 +1.03 (+3.53%) Closing price 06/5/2025 03:59 PM EasternExtended Trading$30.46 +0.16 (+0.51%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
